A5017178386- Antibiotic Resistance in Bacteria
- Vector-borne infectious diseases
- Antibiotic Use and Resistance
- Enterobacteriaceae and Cronobacter Research
- Viral Infections and Vectors
- Travel-related health issues
- COVID-19 Clinical Research Studies
- Escherichia coli research studies
- SARS-CoV-2 and COVID-19 Research
- Blood groups and transfusion
- Yersinia bacterium, plague, ectoparasites research
- Evolution and Genetic Dynamics
- Zoonotic diseases and public health
- Bacterial Identification and Susceptibility Testing
- Data-Driven Disease Surveillance
- Hemoglobinopathies and Related Disorders
- Infectious Diseases and Tuberculosis
- Gut microbiota and health
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- Otolaryngology and Infectious Diseases
- COVID-19 Impact on Reproduction
- Bacteriophages and microbial interactions
- Streptococcal Infections and Treatments
- Vaccine Coverage and Hesitancy
University of Helsinki
2021-2025
Helsinki University Hospital
2016-2025
Abstract Background No licensed human vaccines are available against enterotoxigenic Escherichia coli (ETEC), a major diarrhoeal pathogen affecting children in low- and middle-income countries foreign travellers alike. ETVAX®, multivalent oral whole-cell vaccine containing four inactivated ETEC strains the heat-labile enterotoxin B subunit (LTB), has proved promising Phase 1 1/ 2 studies. Methods We conducted 2b double-blinded, randomized, placebo-controlled trial amongst Finnish to Benin,...
As hospitals have a high prevalence of multidrug-resistant organisms (MDRO), hospitalization abroad indicates for travellers an increased risk acquiring MDRO-and carrying the strains home. Antimicrobial resistance (AMR) rates are highest in (sub)tropics, whereas Europe is considered lower region. Since AMR prevalences vary within Europe, we aimed to gather country-specific data on risks hospitalized travellers.At Helsinki and Uusimaa district Finland, patients over past 12 months...
Abstract Multi-drug resistant (MDR) E. coli constitute a major public health burden globally, reaching the highest prevalence in global south yet frequently flowing with travellers to other regions. However, our comprehension of entire genetic diversity colonising local populations remains limited. We quantified this diversity, its associated antimicrobial resistance (AMR), and assessed impact antibiotic use by recruiting 494 outpatients 423 community dwellers Punjab province, Pakistan....
Convalescent plasma (CP) therapy for COVID-19 infection may have favorable safety but varying efficacy, with concerns about its procoagulant impact. We investigated whether administration of CP to hospitalized patients affects their coagulation profile. Fifty-four randomized in a double-blinded fashion received either placebo, low-titer (LCP) or high-titer (HCP). Donor blood samples were obtained at the time plasmapheresis, while recipient collected before infusion, one day post-infusion and...
We report two cases of louse-borne relapsing fever (LBRF) in young Somali asylum seekers having recently arrived to Finland. They had sought medical attention for a febrile illness. Blood smears were examined suspected malaria, but instead, spirochete shaped bacteria observed. The confirmed as Borrelia recurrentis by PCR and sequencing. patients survived, their treatment was complicated Jarisch-Herxheimer reaction. conclude that LBRF must be considered diagnostic option refugees also the...
Abstract In patients with acute epiglottitis, the possibility of COVID‐19 should be ruled out. Repeated nasofiberoscopy examinations or a tracheostomy, which may produce infectious aerosols, required.
Background While 20–80% of regular visitors to (sub)tropical regions become colonised by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE), those hospitalised abroad often also carry other multidrug-resistant (MDR) bacteria on return; the rates are presumed be highest for interhospital transfers. Aim This observational study assessed MDR bacterial colonisation among patients transferred directly from hospitals Helsinki University Hospital. We investigated predisposing...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
Early in the COVID-19 pandemic, convalescent plasma (CP) emerged as a potentially effective treatment neutralising SARS-CoV-2. CP therapy with high antibody (NAb) titre may benefit outpatients and, sufficient quantities even some hospitalised patients. This study details process of setting up bank, containing high- and low-titre for clinical trial.